EUVIMEDEUVIMED entdecken
Crossref

Benzimidazole‐Based VEGFR‐2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights

Mohamed Atia Dewidar, Heba Abdelrasheed Allam, Hatem A Abdel-Aziz, Mohamed R Elnagar iD, Noha M Ibrahim iD

Drug Development Research · 2026-08 · 87 (5)

DOI: 10.1002/ddr.70339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 01.07.2026. Verfasst von Mohamed Atia Dewidar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Benzimidazoles, Sorafenib, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor receptor‐2 (VEGFR‐2) plays a central role in tumor angiogenesis and remains a well‐established therapeutic target in cancer treatment. In this study, twenty‐six benzimidazole‐based derivatives ( 3a–k , 5a–d , 8a–g , and 10a–d ) were rationally designed to incorporate the essential structural and pharmacophoric features required for effective VEGFR‐2 inhibition, followed by their synthesis and biological evaluation. In vitro kinase assays demonstrated that the synthesized derivatives inhibited VEGFR‐2 with IC 50 values ranging from 0.061 to 1.895 µM. Based on their enzymatic potency, the most active compounds ( 3f , 3h , 3j , 8d , and 8g ) were further investigated for antiproliferative activity against HUVEC, MCF‐7, and HepG2 cell lines. Among them, Compound 3f exhibited IC 50 values of 13.34, 5.32, and 5.02 µM, respectively, showing activity comparable to sorafenib. Evaluation against normal MCF‐10A and Vero cell lines indicated favorable biocompatibility and a reasonable selectivity profile. Mechanistic studies revealed that 3f induced G2/M‐phase arrest, promoted apoptosis, and suppressed cell migration, accompanied by a reduction in VEGFR‐2 protein expression levels. Molecular docking suggested that the synthesized derivatives adopt a binding mode consistent with Type II VEGFR‐2 inhibitors, while in silico ADME and toxicity predictions supported an acceptable toxicity profile and drug‐like characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2BenzimidazolesSorafenibAntineoplastic AgentsProtein Kinase InhibitorsHumansAnimalsCell ProliferationMolecular Docking SimulationApoptosisChlorocebus aethiopsStructure-Activity RelationshipVero CellsCell MovementHep G2 CellsMCF-7 CellsHuman Umbilical Vein Endothelial Cells

Stichwörter der Autor:innen

KinaseVEGFR‐2angiogenesisanticancerbenzimidazolemolecular docking

Substanzen

Vascular Endothelial Growth Factor Receptor-2BenzimidazolesSorafenibAntineoplastic AgentsKDR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Postgraduate Program in Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • National Cancer Institute, Cairo University, Cairo, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Department of Applied Organic Chemistry, National Research Centre, Dokki, Giza, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
  • Department of Pharmacology, College of Pharmacy, The Islamic University, Najaf, Iraq.

ORCID-Profile: Mohamed R Elnagar, Noha M Ibrahim

Zitieren

APA

Dewidar, M. A., Allam, H. A., Abdel-Aziz, H. A., Elnagar, M. R., & Ibrahim, N. M. (2026). Benzimidazole‐Based VEGFR‐2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights. Drug Development Research, 87(5). https://doi.org/10.1002/ddr.70339

Vancouver

Dewidar MA, Allam HA, Abdel-Aziz HA, Elnagar MR, Ibrahim NM. Benzimidazole‐Based VEGFR‐2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights. Drug Development Research. 2026;87(5). doi:10.1002/ddr.70339

BibTeX
@article{Dewidar2026,
  author = {Dewidar, Mohamed Atia and Allam, Heba Abdelrasheed and Abdel-Aziz, Hatem A and Elnagar, Mohamed R and Ibrahim, Noha M},
  title = {Benzimidazole‐Based VEGFR‐2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {5},
  doi = {10.1002/ddr.70339}
}
Kostenlos starten →